Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.50

Atossa Therapeutics (NASDAQ:ATOS - Free Report) had its target price lifted by Ascendiant Capital Markets from $7.25 to $7.50 in a report released on Friday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Several other research firms have also commented on ATOS. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Craig Hallum upgraded Atossa Therapeutics to a "strong-buy" rating and set a $4.00 target price on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Atossa Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $6.17.

Atossa Therapeutics Stock Up 4.7%

Shares of ATOS traded up $0.04 during midday trading on Friday, reaching $0.90. The company had a trading volume of 644,942 shares, compared to its average volume of 777,998. Atossa Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.66. The firm has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.87. The stock has a market cap of $116.27 million, a PE ratio of -4.09 and a beta of 0.92.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts anticipate that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds have recently made changes to their positions in the stock. Gallagher Capital Advisors LLC purchased a new position in shares of Atossa Therapeutics during the fourth quarter worth $25,000. Millennium Management LLC acquired a new position in Atossa Therapeutics in the 4th quarter valued at about $28,000. Two Sigma Advisers LP grew its position in Atossa Therapeutics by 214.1% in the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock valued at $40,000 after acquiring an additional 28,900 shares in the last quarter. Intech Investment Management LLC increased its stake in Atossa Therapeutics by 224.0% during the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company's stock worth $59,000 after purchasing an additional 43,449 shares during the period. Finally, Wells Fargo & Company MN lifted its position in shares of Atossa Therapeutics by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.